Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Estimates By $0.06 EPS

Key Points

• Autolus beat quarterly expectations, reporting an adjusted loss of $0.15 per share versus the $0.21 consensus loss, while revenue reached $45.69 million against estimates of $38.56 million.
• AUCATZYL net product revenue surged to $45.7 million in Q2 2026, prompting management to raise full-year revenue guidance to $140 million–$150 million. Commercial expansion and treatment-center adoption are advancing faster than planned.
• Gross margin improved to 55% from 6% in the prior quarter, and the company expects cash runway into Q2 2028 after drawing $75 million from a credit facility; however, the financing adds future debt obligations.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.06, FiscalAI reports. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The firm had revenue of $45.69 million for the quarter, compared to the consensus estimate of $38.56 million.

Here are the key takeaways from Autolus Therapeutics' conference call:

• AUCATZYL net product revenue rose to $45.7 million in Q2 2026, up from $26.2 million in Q1 and $20.9 million a year earlier. Management raised full-year 2026 revenue guidance to $140 million–$150 million.
• Commercial expansion is progressing faster than planned, with more than 80 U.S. authorized treatment centers already active by midyear and approximately 20 U.K. centers expected by year-end. Management said most activated centers have already treated patients and reported strong physician adoption.
• Gross margin improved sharply to 55% from 6% in Q1, driven by higher manufacturing volumes, production at the U.K. Nucleus facility, operating efficiencies, and cost reductions. The company is targeting a 65%–70% gross margin for the mature adult ALL business within roughly 12–18 months.
• Management outlined multiple upcoming clinical catalysts, including longer-term CARLYSLE lupus data and initial AUTO8 amyloidosis data by year-end 2026, BOBCAT progressive multiple sclerosis data in 2027, and potential pediatric ALL and lupus nephritis milestones in 2027–2028.
• Autolus drew an initial $75 million under a Perceptive Advisors credit facility, with up to $250 million potentially available subject to revenue milestones. Combined with cash, marketable securities, and anticipated revenue, management expects runway into Q2 2028, though the financing increases future debt obligations.

Autolus Therapeutics Trading Up 8.9%

NASDAQ AUTL traded up $0.18 on Tuesday, hitting $2.25. 1,289,334 shares of the company's stock traded hands, compared to its average volume of 1,687,173. Autolus Therapeutics has a 1-year low of $1.17 and a 1-year high of $2.50. The firm's 50-day moving average price is $1.59 and its two-hundred day moving average price is $1.55. The firm has a market capitalization of $600.19 million, a PE ratio of -2.12 and a beta of 2.07.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company raised its stake in shares of Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company's stock valued at $88,000 after buying an additional 11,289 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after buying an additional 11,381 shares during the period. Marex Group plc purchased a new stake in shares of Autolus Therapeutics in the second quarter worth about $28,000. SmartHarvest Portfolios LLC purchased a new stake in shares of Autolus Therapeutics in the fourth quarter worth about $43,000. Finally, Two Sigma Investments LP grew its holdings in Autolus Therapeutics by 17.3% during the third quarter. Two Sigma Investments LP now owns 172,143 shares of the company's stock worth $281,000 after acquiring an additional 25,346 shares during the period. Hedge funds and other institutional investors own 72.83% of the company's stock.

Analyst Upgrades and Downgrades

AUTL has been the topic of several analyst reports. Wall Street Zen raised shares of Autolus Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday. Weiss Ratings lowered Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 31st. Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a research report on Monday, April 20th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Autolus Therapeutics has an average rating of "Moderate Buy" and an average target price of $8.75.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source